Publications
64
Citations
319
Est. group size
~35
Recurring co-author estimate
Active years
58
Publishing since 1969
Asrar Alahmadi's work focuses on lung and other solid-tumor cancers, including small cell and non-small cell lung cancer, hepatocellular carcinoma, and pancreatic cancer. The research covers clinical outcomes, biomarker profiling, immunotherapy responses, and drug targeting strategies such as CDK4/6 inhibitors, alongside studies on disparities in cancer care related to race, insurance, and socioeconomic status. Work spans laboratory-based mechanistic studies, early-phase clinical trials, and large database analyses of treatment outcomes.
Publication output has grown over the last decade, rising from about 1 paper in 2017 to a peak of 15 in 2023, with continued high activity through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Hepatobiliary Progenitor-like Reprogramming in Liver Metastases
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer
Cancer Research · 2026
- GEMINI-NSCLC study: Integrated longitudinal multi-omic biomarker profiling study of non-small cell lung cancer (NSCLC) patients.
Journal of Clinical Oncology · 2025
- Supplementary Data from Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer
2025
- Expanding the Understanding of Polymerase Epsilon in Pancreatic Cancer: Immune Checkpoint Inhibitor Response in Polymerase Epsilon P286R–Mutated Metastatic Pancreatic Adenocarcinoma
JCO Precision Oncology · 2025
- Data from Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer
2024
- 673 Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4 x 4–1BB bispecific antibody, in patients with advanced solid tumors demonstrate favorable safety and biological activity
Regular and Young Investigator Award Abstracts · 2024
- Outcomes of Antineoplastic Immunotherapy at a Large Healthcare Organization: Impact of Provider, Race and Socioeconomic Status
Cancer Management and Research · 2023
- Supplementary Data from Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer
2023
- Supplementary Figures from Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer
2023
- Supplementary Figures from Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer
2023
- Supplementary Data from Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer
2023
- Data from Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer
2023
- Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer
Molecular Cancer Therapeutics · 2022
- Associations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract Cancers After Surgery
Frontiers in Oncology · 2022
- Journal of Clinical Oncology×16
- Journal of the National Comprehensive Cancer Network×5
- Regular and Young Investigator Award Abstracts×4
- Cancer Medicine×3
- Clinical Lung Cancer×2
- Yan Han
Medicine · Indiana University
- Jing Liang
Medicine · The Ohio State University
- Kai He
Medicine · The Ohio State University
- Kevin Ho
Medicine · The Ohio State University
- Lai Wei
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile